A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861 on ClinicalTrials.gov · last registry update 2026-08-27
A small phase 3 — 192 participants, against a typical 424. Due to report March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Mean Percent Change From Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. orforglipron is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 1 time since then.
- Status
- NOT_YET_RECRUITING
- Phase
- P3
- Drug
- orforglipronFoundayo
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 192
- Started
- 2026-12
- Primary completion
- 2028-03 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-08-27 | First seen in registry | Registered as NOT_YET_RECRUITING, P3 |
Primary outcome
Mean Percent Change From Baseline in Body Weight
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the orforglipron page for this molecule’s full trial and approval history.